Abstract: Subject matter of the present invention is a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derived peptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffold for inhibiting HCMV entry for use in a method of treatment in a subject that has been infected by HCMV or for use in a method of prophylaxis of HCMV infection in a subject that has not yet been infected by HCMV.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
July 19, 2022
Assignee:
AiCuris Anti-Infective Cures GmbH
Inventors:
Christian Sinzger, Cora Stegmann, Kerstin Laib Sampaio, Barbara Adler
Abstract: Subject matter of the present invention is a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derived peptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffold for inhibiting HCMV entry for use in a method of treatment in a subject that has been infected by HCMV or for use in a method of prophylaxis of HCMV infection in a subject that has not yet been infected by HCMV.
Type:
Application
Filed:
August 6, 2021
Publication date:
December 9, 2021
Applicant:
AiCuris Anti-Infective Cures GmbH
Inventors:
Christian SINZGER, Cora STEGMANN, Kerstin LAIB SAMPAIO, Barbara ADLER
Abstract: Anti-viral active agents, particularly the free base hemihydrate form of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, as well as methods for the manufacture thereof. Also the use of the above compound in the treatment of human herpes virus infections and in the preparation of pharmaceuticals comprising said compound.
Type:
Application
Filed:
April 2, 2021
Publication date:
September 2, 2021
Applicant:
AiCuris Anti-Infective Cures GmbH
Inventors:
Yogeshwar BACHHAV, Wilfried SCHWAB, Alexander BIRKMANN, Kurt VOEGTLI
Abstract: The present invention relates to the field of anti-viral active agents, particularly the free base hemihydrate form of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide as well as methods for the manufacture thereof. The present invention relates also to the use of the above compound in the treatment of human herpes virus infections and in the preparation of pharmaceuticals comprising said compound.
Type:
Grant
Filed:
November 28, 2017
Date of Patent:
June 1, 2021
Assignee:
AiCuris Anti-Infective Cures GmbH
Inventors:
Yogeshwar Bachhav, Wilfried Schwab, Alexander Birkmann, Kurt Voegtli
Abstract: The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, to pharmaceutical formulations thereof as well as to methods for the production of these salts. The present invention also relates to the use of theses salts and of respective pharmaceutical formulations thereof in methods of treatment and/or prevention of human herpes simplex virus infections, particulary infections caused by HSV-1 and HSV-2.
Type:
Application
Filed:
November 28, 2017
Publication date:
September 17, 2020
Applicant:
AICURIS ANTI-INFECTIVE CURES GMBH
Inventors:
Yogeshwar BACHHAV, Wilfried SCHWAB, Alexander BIRKMANN, Susanne BONSMANN, Thomas GOLDNER
Abstract: The present invention relates to the field of anti-viral active agents, particularly the free base hemihydrate form of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide as well as methods for the manufacture thereof. The present invention relates also to the use of the above compound in the treatment of human herpes virus infections and in the preparation of pharmaceuticals comprising said compound.
Type:
Application
Filed:
November 28, 2017
Publication date:
April 23, 2020
Applicant:
AiCuris Anti-Infective Cures GmbH
Inventors:
Yogeshwar BACHHAV, Wilfried SCHWAB, Alexander BIRKMANN, Kurt VOEGTLI
Abstract: The present invention relates to field of intravaginally applicable devices that release antiviral compounds. In particular, the present invention relates to vaginal rings comprising a matrix releasing at least one antivirally active compound, in particular anti-herpetic compound N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl -N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide (in the following also referred to as “Pritelivir”) or salts thereof. The present invention therefore relates to the treatment and prevention of herpes infections.
Type:
Application
Filed:
June 28, 2018
Publication date:
April 23, 2020
Applicant:
AICURIS ANTI-INFECTIVE CURES GMBH
Inventors:
Yogeshwar BACHHAV, Susanne BONSMANN, Tamara PFAFF, Alexander BIRKMANN, Karl MALCOLM
Abstract: The present invention discloses novel formulations, reconstitutable solid compositions, pharmaceutical compositions, and aqueous injectable formulations of specific amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and organic and/or inorganic acids, their preparation and use as antimicrobial pharmaceutical compositions that are parenterally or orally administrable.
Abstract: The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30° C. to 60° C., and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).
Type:
Grant
Filed:
June 19, 2014
Date of Patent:
October 15, 2019
Assignee:
AICURIS ANTI-INFECTIVE CURES GMBH
Inventors:
Wilfried Schwab, Dirk Jung, Christian Schickaneder, Welljanne Martens, Michael Limmert, Clemens Bothe, Mathias Berwe, Nicole Rindermann
Abstract: Subject matter of the present invention is a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derived peptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffold for inhibiting HCMV entry for use in a method of treatment in a subject that has been infected by HCMV or for use in a method of prophylaxis of HCMV infection in a subject that has not yet been infected by HCMV.
Type:
Application
Filed:
June 27, 2017
Publication date:
May 30, 2019
Applicant:
AiCuris Anti-Infective Cures GmbH
Inventors:
Christian SINZGER, Cora STEGMANN, Kerstin LAIB SAMPAIO, Barbara ADLER
Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
Type:
Grant
Filed:
August 22, 2017
Date of Patent:
November 27, 2018
Assignee:
AiCuris Anti-Infective Cures GmbH
Inventors:
Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
Abstract: The present invention is directed to a process for making Substituted Quinazoline Compounds of formula (I): which are useful for the treatment and prophylaxis of HCMV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5 -(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2 -pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
Type:
Grant
Filed:
August 31, 2015
Date of Patent:
February 13, 2018
Assignee:
AICURIS ANTI-INFECTIVE CURES GMBH
Inventors:
Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
Type:
Application
Filed:
August 22, 2017
Publication date:
December 7, 2017
Applicant:
AiCuris Anti-Infective Cures GmbH
Inventors:
Wilfried SCHWAB, Alexander BIRKMANN, Kerstin PAULUS, Kurt VÖGTLI, Dieter HAAG, Stephan MAAS, Kristian RUEPP
Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
Type:
Grant
Filed:
August 31, 2015
Date of Patent:
March 14, 2017
Assignee:
AICURIS ANTI-INFECTIVE CURES GMBH
Inventors:
Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
Abstract: The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30° C. to 60° C., and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).
Type:
Application
Filed:
June 19, 2014
Publication date:
May 26, 2016
Applicant:
AICURIS ANTI-INFECTIVE CURES GMBH
Inventors:
Wilfried SCHWAB, Dirk JUNG, Christian SCHICKANEDER, Welljanne MARTENS, Michael LIMMERT, Clemens BOTHE, Mathias BERWE, Nicole RINDERMANN
Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
Type:
Grant
Filed:
April 9, 2015
Date of Patent:
April 17, 2018
Assignee:
AICURIS ANTI-INFECTIVE CURES GMBH
Inventors:
Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Thomas Lampe, Susanne Nikolic, Jurgen Reefschlager, Rudolf Schohe-Loop, Frank Sussmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jorg Keldenich, Dieter Lang, Peter Nell